Literature DB >> 12034676

Intravitreal triamcinolone in recurrence of choroidal neovascularisation.

P L Penfold.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12034676      PMCID： PMC1771174          DOI： 10.1136/bjo.86.6.600

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  17 in total

1.  Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.

Authors:  R P Danis; T A Ciulla; L M Pratt; W Anliker
Journal:  Retina       Date:  2000       Impact factor: 4.256

2.  Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis.

Authors:  S Young; G Larkin; M Branley; S Lightman
Journal:  Clin Exp Ophthalmol       Date:  2001-02       Impact factor: 4.207

3.  Intravitreal triamcinolone and elevated intraocular pressure.

Authors:  R J Wingate; P E Beaumont
Journal:  Aust N Z J Ophthalmol       Date:  1999-12

4.  Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model.

Authors:  T A Ciulla; M H Criswell; R P Danis; T E Hill
Journal:  Arch Ophthalmol       Date:  2001-03

5.  Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy.

Authors:  J B Jonas; J K Hayler; A Söfker; S Panda-Jonas
Journal:  Am J Ophthalmol       Date:  2001-04       Impact factor: 5.258

6.  Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study.

Authors:  R J Antcliff; D J Spalton; M R Stanford; E M Graham; T J ffytche; J Marshall
Journal:  Ophthalmology       Date:  2001-04       Impact factor: 12.079

7.  Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration.

Authors:  P L Penfold; L Wen; M C Madigan; M C Gillies; N J King; J M Provis
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 8.  Immunological and aetiological aspects of macular degeneration.

Authors:  P L Penfold; M C Madigan; M C Gillies; J M Provis
Journal:  Prog Retin Eye Res       Date:  2001-05       Impact factor: 21.198

9.  Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up.

Authors:  J K Challa; M C Gillies; P L Penfold; J F Gyory; A B Hunyor; F A Billson
Journal:  Aust N Z J Ophthalmol       Date:  1998-11

10.  The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization.

Authors:  A N Antoszyk; J L Gottlieb; R Machemer; D L Hatchell
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993       Impact factor: 3.117
View more
  6 in total

1.  Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration.

Authors:  J B Jonas; I Kreissig; R F Degenring
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

2.  Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

Authors:  J B Jonas; I Kreissig; P Hugger; G Sauder; S Panda-Jonas; R Degenring
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

3.  Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo.

Authors:  U H M Spandau; G Sauder; U Schubert; H-P Hammes; J B Jonas
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

4.  Indocyanine green-mediated photothrombosis with intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization in age-related macular degeneration.

Authors:  J Fernando Arevalo; Reinaldo A Garcia; Aristides J Mendoza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-05-20       Impact factor: 3.117

5.  Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone.

Authors:  T Kube; M Sutter; R Trittler; N Feltgen; L L Hansen; H T Agostini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-05-20       Impact factor: 3.117

Review 6.  [Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases].

Authors:  J B Jonas; I Kreissig; B Kamppeter; R F Degenring
Journal:  Ophthalmologe       Date:  2004-02       Impact factor: 1.059
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.